ViroPharma Provides 2013 Outlook

                       ViroPharma Provides 2013 Outlook

- Provides 2013 Annual Net Sales Guidance of Up to $475 Million -

PR Newswire

EXTON, Pa., Jan. 7, 2013

EXTON, Pa., Jan. 7, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq:
VPHM) today announced that Vincent Milano, president and chief executive
officer of ViroPharma, will provide an overview of the company's business,
including additional maribavir clinical trial data, during the 31^st Annual
J.P. Morgan Healthcare Conference. The presentation will be webcast live at
6:30 P.M. ET (3:30 P.M. PT) on Tuesday, January 8, 2013 and may be accessed
via the company's website at The conference is being held
at the Westin St. Francis Hotel in San Francisco. The company expects to
release full-year 2012 financial results later in the first quarter of 2013.

"2012 represented a new beginning for ViroPharma. We believe our execution and
achievements throughout the global organization during the year position the
company very well for not only success in 2013, but also provides the
opportunity for tremendous growth for our shareholders in the years ahead,"
stated Milano. "ViroPharma has moved beyond Vancocin^® (vancomycin
hydrochloride capsules, USP)  and now has a geographically diverse commercial
portfolio and a robust, maturing development pipeline. The continued success
of Cinryze^® (C1 esterase inhibitor [human]), with unaudited 2012 U.S. net
sales ofapproximately $321 million, driven by over 900 active patients on
prophylactic therapy, led the way. The commercial launches of Cinryze,
Buccolam^® (midazolam, oromucosal solution) and Plenadren^® (hydrocortisone,
modified release tablet) in Europe are also beginning to gain traction, and we
believe that these products will ultimately become strong contributors to our
overall growth in the years ahead."

Milano continued, "As we advance through 2013, we believe that our progress
will clearly show ViroPharma to be well along the path that we laid out in our
analyst day event this past September. The financial guidance we are providing
this morning reflects strong enthusiasm for our products from our patients and
their caregivers. We expect 2013 will also be a significant year in the
advancement of our development programs. Success in 2013 could position us to
be entering into phase 3 development of several products in 2014. As always,
our global team embraces the challenges in front of us and is poised to
continue executing on our long term plans which are designed to ultimately
drive tremendous growth for our shareholders."

As a reminder to our shareholders, the 2012 Cinryze net sales estimate of
approximately $321 million is an unaudited amount, of which approximately $311
to $312 million represents actual patient demand and the remainder represents
increase in channel inventories. The company also anticipates that the
remaining channel inventory increase to complete return to normalized levels
will occur in the first quarter of 2013.

Looking ahead in 2013
ViroPharma is providing guidance for the year 2013 as a convenience to
investors. The following guidance provided by ViroPharma are projections,
based upon numerous assumptions, all of which are subject to certain risks and
uncertainties. For a discussion of the risks and uncertainties associated with
these forward looking statements, please see the Disclosure Notice below.

For the year 2013, ViroPharma expects the following:

  oWorldwide net product sales are expected to be $450 to $475 million;
  oNet North American Cinryze sales are expected to be $390 to $400 million;
  oResearch and development (R&D) and selling, general and administrative
    (SG&A) expenses are expected to be $240 to $260 million.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few if any clinical therapeutic options. ViroPharma is developing a
portfolio of therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency,
cytomegalovirus (CMV); and recurrent C. difficile infection (CDI). Our goal is
to provide rewarding careers to employees, to create new standards of care in
the way serious diseases are treated, and to build international partnerships
with the patients, advocates, and health care professionals we serve.
ViroPharma's commercial products address diseases including hereditary
angioedema (HAE), seizures, adrenal insufficiency and C. difficile-associated
diarrhea (CDAD); for full U.S. prescribing information on our products, please
download the package inserts at; the
prescribing information for other countries can be found at

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's web site, The company encourages investors to
consult these sections, and the risk factors included in our periodic filings
with the Securities and Exchange Commission for more information on ViroPharma
and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements
that involve a number of risks and uncertainties. Forward-looking statements
provide our current expectations or forecasts of future events. Forward
looking statements in this press release include our financial guidance for
2013, our ability to successfully execute our business plans and if
successful, to provide the opportunity for growth for our shareholders in the
years ahead, the rate of future growth, the rate at which we are able to
identify new Cinryze patients in the United States, our ability to continue to
successfully commercialize our products in the United States and Europe, our
ability to conduct additional clinical studies in the timeframes we
anticipate, whether the results of such clinical studies will support
additional studies, and the timing of channel inventory fluctuations.

Our actual results may vary depending on a variety of factors, including:

  oour ability to continue to identify Cinryze patients in the United States
    and Europe at the rate we anticipate and the total number of potential
    Cinryze patients in the United States and Europe;
  othe size of the market, future growth potential and market share for
    Cinryze in the United States, Europe and other territories;
  othe size of the market, future growth potential and market share for
    Cinryze, Buccolam and Plenadren in Europe;
  othe availability of sufficient third party or governmental payer
    reimbursement for each of our products in the United States and Europe;
  ofluctuations in wholesaler order patterns and inventory levels;
  ocompetition from the approval of products which are currently marketed for
    other indications by other companies or new pharmaceuticals and
    technological advances to treat the conditions addressed by Cinryze,
    Vancocin, Buccolam and Plenadren;
  ochanges in prescribing or procedural practices of physicians, including
    off-label prescribing of products competitive with Vancocin, Cinryze,
    Buccolam and Plenadren;
  omanufacturing, supply or distribution interruptions, including but not
    limited to our ability to acquire adequate supplies of Cinryze and our
    other products in order to meet demand for each product;
  oour ability to receive regulatory approval for the use of Cinryze for
    additional indications and routes of administration and in additional
    territories in the timeframes we anticipate or at all;
  othe impact of changes to U.S. or E.U. healthcare legislation or
    reimbursement practices;
  oactions by the FDA and EMA or other government regulatory agencies;
  othe timing and results of anticipated events in our clinical development
    programs including studies with Cinryze subcutaneous formulation, Cinryze
    for antibody mediated rejection, maribavir for treatment of CMV infections
    in transplant recipients, as well as VP20621 for recurrence of C.
    difficile; and,
  othe timing and nature of potential business development activities related
    to our efforts to expand our current portfolio through in-licensing or
    other means of acquiring products in clinical development or marketed

There can be no assurance that we will conduct additional studies or that we
will be successful in gaining regulatory approval of Cinryze for additional
indications, routes of administration or in additional territories. The entry
of competing generic products following FDA approval in April 2012 has and
will continue to significantly affect our sales of Vancocin and our financial
performance. Biologics such as Cinryze require processing steps that are more
difficult than those required for most chemical pharmaceuticals, and as a
result, Sanquin, our manufacturer of Cinryze has received observations on Form
483 which require us to continue to meet commitments made to the FDA related
to various manufacturing issues. In the event Sanquin fails to meet these
commitments, the FDA may take actions that limit our ability to manufacture
Cinryze. In the event Sanquin is not able to manufacture the anticipated
volume of product at the industrial scale as a result of either FDA
requirements, batch failures, variability in batch yields, required
maintenance or other causes, we may not be able to satisfy patient demand or
build safety stock. Our inability to obtain adequate product supplies to
satisfy our patient demand may create opportunities for our competitors and we
will suffer a loss of potential future revenues. These factors, and other
factors, including, but not limited to those described in ViroPharma's Annual
report on Form 10-K for the year ended December 31, 2011 and our subsequent
Quarterly Reports on Form 10-Q for the periods ended March 31, 2012, June 30,
2012 and September 30, 2012 could cause future results to differ materially
from the expectations expressed in this press release. The forward-looking
statements contained in this press release may become outdated over time.
ViroPharma does not assume any responsibility for updating any forward-looking

SOURCE ViroPharma Incorporated

Contact: ViroPharma Incorporated Contacts: Will Roberts (Media), Corporate
Communications, +1-610-321-6288; or Robert A. Doody Jr. (Investors), Investor
Relations, +1-610-321-6290
Press spacebar to pause and continue. Press esc to stop.